Lyell Immunopharma's market cap is currently $317.18M. The company's EPS TTM is $-2.89; its P/E ratio is ―; Lyell Immunopharma is scheduled to report earnings on August 12, 2025, and the estimated EPS forecast is $-2.64. See an overview of income statement, balance sheet, and cash flow financials.
